Safety, pharmacokinetics, and pharmacodynamics of TG103, a novel long-acting GLP-1/Fc fusion protein after a single ascending dose in Chinese healthy subjects
-
Published:2023-06
Issue:
Volume:185
Page:106448
-
ISSN:0928-0987
-
Container-title:European Journal of Pharmaceutical Sciences
-
language:en
-
Short-container-title:European Journal of Pharmaceutical Sciences
Author:
Jin Jiangli, Cui Gang, Mi Na, Wu Wei, Zhang Xin, Xiao Chunyan, Wang Jing, Qiu Xueying, Han MaiORCID, Li Ziyan, Wang Lei, Lu Tong, Niu Huikun, Wu Zhaoxi, Li Jintong
Subject
Pharmaceutical Science
Reference42 articles.
1. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial;Rubino;JAMA,2021 2. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial;Davies;JAMA,2015 3. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults;van Can;Int. J. Obes. (Lond),2014 4. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in Type 2 diabetes in a randomized controlled Trial (AWARD-5);Nauck;Diabetes. Care,2014 5. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6);Buse;Lancet,2009
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|